Clinic Roundup

• Synageva BioPharma Corp., of Lexington, Mass., said a 12-week Phase I/II extension study data published in Hepatology showed that for seven patients with lysosomal acid lipase deficiency who completed dosing with sebelipase alfa, mean percent decreases for ALT and AST from both the initial baseline to week 12 were 52 percent and 36 percent, respectively (p < 0.05 for both).